Skeletal responses to romosozumab after 12 months of denosumab

por McClung, Michael R., Bolognese, Michael A., Brown, Jacques P., Reginster, Jean‐Yves, Langdahl, Bente L., Shi, Yifei, Timoshanko, Jen, Libanati, Cesar, Chines, Arkadi, Oates, Mary K.
Publicado 2021

Influence of subject discontinuation on long-term nonvertebral fracture rate in the denosumab FREEDOM Extension study

por Adachi, Jonathan D., Bone, Henry G., Daizadeh, Nadia S., Dakin, Paula, Papapoulos, Socrates, Hadji, Peyman, Recknor, Chris, Bolognese, Michael A., Wang, Andrea, Lin, Celia J. F., Wagman, Rachel B., Ferrari, Serge
Publicado 2017

Romosozumab Enhances Vertebral Bone Structure in Women With Low Bone Density

por Poole, Kenneth ES, Treece, Graham M, Pearson, Rose A, Gee, Andrew H, Bolognese, Michael A, Brown, Jacques P, Goemaere, Stefan, Grauer, Andreas, Hanley, David A, Mautalen, Carlos, Recknor, Chris, Yang, Yu‐Ching, Rojeski, Maria, Libanati, Cesar, Whitmarsh, Tristan
Publicado 2021

Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures

por Austin, Matthew, Yang, Yu-Ching, Vittinghoff, Eric, Adami, Silvano, Boonen, Steven, Bauer, Douglas C, Bianchi, Gerolamo, Bolognese, Michael A, Christiansen, Claus, Eastell, Richard, Grauer, Andreas, Hawkins, Federico, Kendler, David L, Oliveri, Beatriz, McClung, Michael R, Reid, Ian R, Siris, Ethel S, Zanchetta, Jose, Zerbini, Cristiano AF, Libanati, Cesar, Cummings, Steven R
Publicado 2012